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crease the dose/frequency of octreotide-LAR as 2nd-line therapy in patients with
uncontrolled symptomsup to 60mg every 4weeks or up to 40mg every 3 or 4weeks
for refractory carcinoid syndrome; and 3) as 3rd-line therapy, antiangiogenic ther-
apy may be active in patients with carcinoid tumors. CONCLUSIONS: Treatment
consensus obtained in this study is concordant with NCCN recommendations. The
Delphi process, however, permittedmore detailedmedical treatment guidelines in
a range of key areas in midgut NETs.
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OBJECTIVES: Gastrointestinal neuroendocrine tumors (NETs) are rare and current
treatment guidelines lack specificity in some clinical areas. We present a panel
consensus on medical treatment of well-differentiated (grade 1-2 tumors) unre-
sectable non-pancreatic non-midgut NETs. METHODS: NET treatment appropri-
ateness ratings were collected using the RAND/UCLA Delphi process. We recruited
physician experts (criteria: specialty, geography, practice), reviewed NET treat-
ment literature, and collected 2 rounds of ratings (before and after a face-to-face
meeting) from the experts. Experts and the moderator were blinded to the funding
source. Patient scenarios (rated on a 1-9 scale indicating appropriateness of various
interventions for a given scenario) were labeled as appropriate, inappropriate, or
uncertain. Scenarios with 2 ratings from 1-3 and 2 from 7-9 range were consid-
ered to have disagreement and were not assigned an appropriateness rating.
RESULTS: Ten panelists had amean age of 50.4 years. Specialties representedwere
medical and surgical oncology, interventional radiology, and gastroenterology, and
all practices were affiliated with academic institutions. Panelists had practiced
between 6-33 years. Among 202 non-midgut rated scenarios, disagreement de-
creased from 16.2% (32 scenarios) before the meeting to 3% (6) after. In the 2nd
round, 42.1% (85 scenarios) were rated inappropriate, 34.2% (69) were uncertain,
and 20.8% (42) were appropriate. Consensus statements from the scenarios in-
clude: 1) observation is appropriate in patients with no symptoms and low-volume
radiographically-stable disease; 2) somatostatin analogs may be appropriate in
patients with secretory symptoms; and 3) everolimus or interferon- can be con-
sidered in patients who progressed radiographically or symptomatically on soma-
tostatin analogs. CONCLUSIONS: We obtained appropriateness ratings of variety
medical therapies in NETs from expert physicians. The Delphi process enabled
participants to systematically quantify their assessment of the literature in a valid
and reliable way while improving overall panel consensus on the appropriateness
of medical therapies in non-midgut NETs.
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OBJECTIVES: Tobacco use following cancer diagnosis is a serious concern for neg-
ative health outcomes. Despite ill-effects of tobacco among cancer patients and
negative implications for treatment, many patients continue to use tobacco. On-
cologists have a pivotal role in promoting tobacco cessation throughout treatment.
This study assessed knowledge, readiness, and willingness to conduct and pro-
mote tobacco cessation counseling among a national sample of currently licensed
practicing US Oncology providers. METHODS: A brief survey was administered in
July 2011 via e-mail (N3006) and US postal mail (N1000). Samples were obtained
fromSK&A Information Services, Inc., which used verified addresses and broadcast
e-mail surveyswith one follow-up. Response rateswere 0.6% for e-mail (N19) and
9.6% for postal mail (N96), with a 2.9% overall response rate (N115). RESULTS:
Results showed a majority of oncologists do the following often/almost always
with patients: ask about tobacco use (96.6%); document tobacco use (93.1%); discuss
tobacco use as a cancer risk factor (87.9%); counsel patients on quitting (72.8%); and
assess readiness to quit (68.7%). Findings, however, also reported a majority of
oncologists do the following never/rarely with patients: provide information about
secondhand tobacco smoke (53.5%); provide information on quitlines (59.7%); pro-
vide brochures and self-help guides (64.3%); and follow the 5A’s model for tobacco
treatment (68.6%). On a scale of 0-10, providers indicated they were generally com-
fortable providing cessation counseling [mean7.0; SD2.4]; however, providers
were lesswilling to participate in a tobacco cessation training program for assisting
patients with quitting [mean5.2; SD3.4]. CONCLUSIONS: Findings suggest on-
cology providers are asking, documenting use, and counseling patients who con-
tinue to use tobacco during treatment. Education targeting providers can increase
knowledge and practices related to the 5A’s treatment model, promoting quitline
and self-help information for patients. Effective strategies increasing providerwill-
ingness to attend tobacco treatment training sessions should also be encouraged.
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OBJECTIVES: The main objective was to determine the chemotherapy treatment
and outcome.METHODS:Datawas collected from1 June 2008 till 31 December 2008
in Hospital Kuala Lumpur (HKL) using web-based application. Survival data would
be obtained via linkage with Registration Department after four years. Data anal-
ysis was with STATA statistical software. RESULTS: The total number of patients
was 1192.There were 56% females and the most common age group was 50-59
years. The major ethnic groups were Malay (46.5%), Chinese ( 37.3%) and Indians (
13.8%). Most patients at the oncology clinic at HKL have good performance status
with ECOG 0-1 (61.5%). The most prevalent cancers were breast cancer (24.5%),
colorectal cancer( 17.4%), bronchus and lung cancer 8.6%, cervical cancer 6.5% and
nasopharyngeal cancer (NPC) 6.2%. Most solid tumours were treated by multimo-
dality. 48.8% received 2 or more modalities . There were 547 patients (45.9%) that
received radiotherapy and 32.2% that received chemotherapy. 384 patients were
given cytotoxic chemotherapy .Most patients (84,1%) received just one regime. The
most common regime was a combination of Fluorouracil, Epirubicin and Cyclo-
phosphamide ie FEC (16.4%.) The most often used cytotoxic drugs used were Fluo-
rouracil (26.3%), Cisplatin (15%) followed by Cyclophosphamide (9.9%), Epirubcin
(7.3%), Capecitabine ( 6.4%), Docetaxel (4.2%), Gemcitabine (3.7%). The most often
used route of administration was intravenous ( 92.6%) mostly infusion as opposed
to bolus. Capecitabine was the cytotoxic dug that was the most widely used in the
oral form.CONCLUSIONS:This is only sub-study of a long term research that began
in 2008 in HKL.. Patterns in chemotherapy usage would change as new drugs
emerged in the Formulary. The database would be sustained as a platform for
future researches and for survival analysis. (283 words).
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OBJECTIVES: In 2001, Thailand implemented the 30 Baht Scheme, a public insur-
ance scheme that covers the poor and uninsured and pays providers through a
capitated payment scheme. Our objective is to evaluate the impact of the 30 Baht
Scheme on use of medicines in Thailand for three non-communicable diseases:
cancer, cardiovascular disease, and diabetes. METHODS: We used an interrupted
time series design to measure the impact of the 30 Baht Scheme on total pharma-
ceutical market volume and market share. We used IMS Health data on quarterly
purchases of medicines from hospital and retail pharmacies from 1998 to 2006.
RESULTS: The 30 Baht Schemewas associatedwith long-term increases in hospital
sector sales of medicines for conditions that can be adequately treated in outpa-
tient and primary care settings (e.g., diabetes, high cholesterol and high blood
pressure). The policy was associatedwith no change in sales ofmedicines formore
life-threatening diseases, which are more appropriately treated in secondary or
tertiary settings (e.g., myocardial infarction, stroke and cancer). The majority of
sales were for essential medicines, yet there were also post-policy increases for
non-essential medicines. Immediately following the reform, there was a signifi-
cant shift in hospital sector market share by licensing status for most classes of
medicines. We observed large increases in government-produced products, pri-
marily at the expense of branded generics.CONCLUSIONS:Our results suggest that
expanding health insurance coverage with a medicines benefit to the entire Thai
population increased the volume of medicine sales in primary care hospitals. Our
study, however, also suggests that implementation of the 30 Baht Scheme may
have been associated with possibly undesirable effects: increased use of non-es-
sential medicines and decreased use of less expensive generics and medicines in
secondary and tertiary settings. Thorough evaluation of desired and undesired
effects of universal health insurance programs are urgently needed.
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OBJECTIVES: To compare the demographic, clinical and treatment characteristics
of post-menopausal women with advanced ER/HER2- breast cancer (BC) treated
with aromatase inhibitors (AI) who experienced 0 or 1 AI failure (AIF).METHODS:
Women  55 years old, newly diagnosed with metastatic ER/HER2- BC (index)
were identified from the 2006-2010 Thomson Reuters MarketScan databases. Patients
in the 6-month pre- or variable post-index periods treated with endocrine (ET:
tamoxifen, fulvestrant) or AI (anastrozole, letrozole, or exemestane) therapy (ER)
and not with trastuzumab or lapatinib (HER2-), with no pre-index diagnosis of
primary cancer other than BC, and post-index treatmentwith 1 AI were retained.
AIFwas defined post-index as a switch to an alternative AI, ET, or chemotherapy, or
AI discontinuation with no further BC treatment. RESULTS: Among 4274 ER/
HER2- BC patients studied, 61% had 1 AIF (80% had 1 and 20% had 2AIFs). There
was no difference in pre-index AI use (54.4% no AIF, 51.8% AIF; p0.093). At index,
AIF patientsweremore likely to beMedicare-eligible (57% vs. 51%)with liver (7% vs.
4%), lung (10% vs. 8%), bone (56% vs. 48%), and brain (7% vs. 5%) metastases, all
p0.03. Mean follow-up days was shorter for AIF patients (486 vs. 522, p0.006).
First line AI and ET treatments were respectively 95% and 5% for AIF and 97% and
3% for no AIF patients. The most common first line therapy was anastrazole (49%
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noAIF 42%AIF). Overall, with each subsequent line of therapy the proportion of AIF
patients taking fulvestrant increased. In addition, of those with AIF, 35% (n905)
switched to chemotherapy prior to study end. CONCLUSIONS: The majority of
ER/HER2-metastatic breast cancer patients treatedwith AIs will fail at least 1 line
of therapy. Prior AI treatment did not appear associated with future AI failure.
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OBJECTIVES: To describe patients with metastatic melanoma being treated with
mono-therapy, dacarbazine (DTIC) or granulocyte-macrophage colony-stimulating
factor (GM-CSF). METHODS: Using a large US medical claims database, patients
were identified between 2005 and 2010 using 2 melanoma diagnoses (ICD-9-CM:
172.xx, V10.82) and 2 diagnoses for metastasis (ICD-9-CM: 197.xx, 198.xx). Pa-
tients who received mono-therapy with DTIC or GM-CSF as the first documented
drug therapy after metastatic diagnosis were identified. Patient demographic and
clinical characteristics and treatment duration were compared between patients
treated with DTIC and those who received GM-CSF. Furthermore, comparisons
were also made between the two treatment groups after 1-to-1 matching on age,
gender, and baseline comorbidities. RESULTS: A total of 81 patients with meta-
static melanoma receiving first-line DTIC and 24 patients with metastatic mela-
noma receiving first-line GM-CSF were included in this analysis. On average, DTIC
patients were 8.5 years older (p  0.009) and had higher baseline Charlson Comor-
bidity Index scores (D0.43, p  0.005) than GM-CSF patients. The mean duration of
first line treatment was 94 days on DTIC and 135 days on GM-CSF. Themean length
of follow-up from the start of first line was 257 days on DTIC and 451 days on
GM-CSF. After each GM-CSF patient was matched with a DTIC patient on age,
gender, and baseline Charlson Comorbidity Index score, the mean duration of first
line treatment was 79 days on matched DTIC and 135 days on GM-CSF, and the
mean length of follow-up from the start of first line was 317 days onmatched DTIC
and 451 days on GM-CSF. CONCLUSIONS: Patients withmetastatic melanomawho
received DTIC treatment were older and had higher comorbidity index scores but
shorter treatment duration than those who received GM-CSF; the difference in
treatment duration remained after DTIC patients were matched with GM-CSF pa-
tients on age, gender and comorbidity index scores.
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OBJECTIVES: Lapatinib is an oral dual tyrosine kinase inhibitor that has been
shown to improve time to progression when combined with capecitabine versus
capecitabine monotherapy in women with HER2 MBC previously treated with
trastuzumab. Data on health care utilization and costs among women receiving
lapatinib in typical clinical practice are scarce. METHODS: This was retrospective
observational descriptive study of health care utilization and costs among women
receiving lapatinib after treatment with trastuzumab for MBC in the Thomson
MedStatMarketScan Commercial andMedicare health insurance claims databases
(1/2000-3/2010). Monthly utilization and costs were calculated for the 12 months
prior to initiation of lapatinib (pre-treatment period), the lapatinib treatment pe-
riod, and the post-treatment period (end of lapatinib treatment to end of
study/disenrollment). RESULTS: Mean (SD) age was 52(8) and 72(6) years in Com-
mercial (n572) andMedicare (n94) patients respectively. Lapatinib was initiated
in combination w/capecitabine in 63% and w/trastuzumab in 22% of patients. Me-
dian time to lapatinib discontinuation was 7.4 months. The mean(SD) number of
visits/month declined from 6.1(3.0) during pre-treatment to 5.5(3.5) during treat-
ment, and to 4.6(3.9) during post-treatment. The mean(SD) number of inpatient
days/month increased progressively from 0.24(0.52) during pre-treatment, to
0.53(1.39) during treatment and 0.96(2.52) post-treatment. Mean(SD) lapatinib
costs/month during treatment were $2,097($877). Mean(SD) trastuzumab costs/
month were $2,762($2,020), $722($1,731), and $1,166($2,134) during pre-treatment,
treatment, and post-treatment, respectively. Correspondingmean(SD) chemother-
apy costs/month were $1,355($1,898), $1,496($1,698), and $1,437($2,729), respec-
tively, while corresponding mean(SD) chemotherapy administration costs/month
were $508($477), $189($289), and $326($516) respectively.Mean(SD) other (including
inpatient) costs/month were $5,446($4,680), $5,564($7,198), and $6,880($9,726), re-
spectively. Mean(SD) total costs/month were $10,071($6,056), $10,067($7,695), and
$9,809($10,853), respectively. CONCLUSIONS: In this sample of women receiving
lapatinib after treatment with trastuzumab for MBC, monthly health care costs
were similar during lapatinib treatment versus prior to treatment, despite progres-
sively increasing inpatient utilization and costs, potentially reflecting disease pro-
gression over time.
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OBJECTIVES: Iron deficiency anemia is commonly treated with intravenous (IV)
iron in oncology, especially in combination with erythropoiesis-stimulating
agents. Central venous access port – PortaCath (PAC) – is used to provide long-term
venous access and to deliver chemotherapy in this setting. There is a lack of data,
however, on the use of PAC for the administration of IV iron in cancer patients. The
aim of this survey was to assess the frequency of this practice, and the reasons
supporting it.METHODS: FERPAC was a declarative survey conducted in France. A
total of 497 oncologists/hematologists were interviewed on their practices regard-
ing their use of IV iron. Answers were collected and registered into a central-based
server. RESULTS: A total of 141 questionnaires were collected. Most used IV irons
were iron sucrose and ferric carboxymaltose, for which respectively 77.4% and
77.6% of physicians reported to use the PAC for the administration. The main
reasons for using the PAC were the easy way of administration (28.2%) and the
preservation of patient venous capital (26.1%), given that efficacy and safety were
expected to be at least acceptable or even as good as peripheral administration. IV
iron administration was planned strictly after chemotherapy (45.7%), strictly be-
fore (37.2%), or without any preference (17.0%). Reasons for not using the PACwere
either a history of thrombosis (45.1%) or potential drug-drug interactions (17.7%).
CONCLUSIONS: IV irons are currently commonly administered through the PAC in
cancer patients in France. Further studies are needed to confirm the efficacy and
safety of the administration of IV iron through PAC.
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OBJECTIVES: To determine the utilization and predictors of Cyclophosphamide-
Methotrexate-Fluorouracil (CMF) chemotherapy in women with early stage breast
cancer.METHODS:A longitudinal studywas conducted including patients 66 years
and above, diagnosed with stage I-III breast cancer using SEER cancer registry data
linkedwithMedicare claims. Patientswere divided into two groups as those receiv-
ing CMF chemotherapy and those receiving other chemotherapy. A patient was
considered as receiving CMF chemotherapy if she started chemotherapywithin six
months and had a claim of Cyclophosphamide, Methotrexate and 5-Fluorouracil
within one year of diagnosis. Multiple logistic regression was conducted to assess
the predictors of CMF chemotherapy use. RESULTS: A total of 11,322 women re-
ceived chemotherapy within the first six months and 24.4% of these (n  2758)
received CMF chemotherapy. A patient had 2.3 times greater odds of receiving CMF
chemotherapy with each year increase in age. Patients who received a lymph node
dissection had 1.4 times greater odds of receiving CMF chemotherapy than patients
who did not receive it. Patients with stage II tumor had 1.5 times greater odds of
receiving CMF chemotherapy than stage I patients. CMF use decreased by 23%with
estrogen receptor positivity and 18% when radiation was administered to the pa-
tient. Patients with Charlson’s comorbidity index  1 were 16% more likely to
receive CMF chemotherapy than patients who had a Charlson’s comorbidity score
of 0. CMF use decreased overall with time. CONCLUSIONS: This study found that
age, comorbidity index, estrogen receptor status, radiation and lymph node dissec-
tion were significant predictors of CMF chemotherapy. The use of CMF chemother-
apy increased with age, comorbidity index and lymph node dissection and de-
creased with estrogen receptor positivity and irradiation. The declining time trend
in the use of CMF chemotherapy probably indicates the increased use of newer
chemotherapy regimens like the Anthracycline and Taxane based regimens.
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OBJECTIVES: Evidences-based literature has confirmed the effectiveness of radia-
tion therapy (RT) following breast conserving surgery (BCS); thus several practice
guidelines recommend RT after BCS. This study explored factors associated guide-
line compliance among young women with insurance because compliance in this
population is not well-understood. METHODS: Using the 2004-2009 MarketScan®
Research Database, we identified our study cohort as women who had a BCS be-
tween July 1, 2004 and December 31, 2008, and had continuous enrollment from 6
months before to 12 months after the date of BCS. We excluded patients who had
mastectomy within 3 months of BCS. We used Pearson Chi-Squared test and mul-
tivariate logistic regression to ascertain factors associated the receipt of RT within
one year of BCS. We performed Hosmer-Lemeshow goodness-of-fit and other
model diagnostic tests to determine the finalmodel specification and conducted all
analyses using SAS® 9.2 and Stata® 11.0 software. RESULTS: A total of 20,756 of the
24,011 (86.44%) BCS patients received RTwithin a year of their surgery. Results from
the logistic regression showed that the odds of RT increased with age, compared
with patients under 40, the odds ratio was 1.63 (95% confidence interval: 1.40-1.90),
1.86 (1.61-2.16), and 2.04 (1.73-2.39) for those in 40-49, 50-59, and  60 age group,
respectively. Patients who did not enroll in HMOs (1.27; 1.17-1.37) and was primary
insurance policy holder (1.31; 1.21-1.41)were significantlymore likely to receive RT.
Comparewith patients resided in the Northeast region, those in theWest were less
likely to receive RT (0.71; 0.62-0.82). Positive association with hospital density was
also observed (1.17; 1.04-1.31). CONCLUSIONS: Although the compliance rate
among young women with employment-based insurance was higher than that
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